Top
image credit: Freepik

FDA Panel Says No to MDMA as Treatment for PTSD

June 5, 2024

Via: Drugs.com
Category:

A U.S. Food and Drug Administration advisory panel on Tuesday voted against recommending the psychedelic MDMA for the treatment of post-traumatic stress disorder (PTSD).

In a 10-1 vote, the panel determined the evidence amassed so far fails to show the controversial drug’s benefits outweigh its risks, the Associated Press reported.

During the meeting, panel members pointed to flawed study data and significant drug risks, including the potential for heart problems, injury and abuse.

Read More on Drugs.com